|
|
|
|
 Dr Ying Luo,
Chairman and CEO Shanghai Genomics, Inc/ GNI Ltd., China Dr. Ying Luo joined Peking Union Medical College to study medicine in 1982 and earned his Ph.D. degree of Biomedicine at the University of Connecticut Health Center of the United States in 1986. His postdoctoral research was on HIV gene regulation at the University of California at San Francisco in 1992. From 1993 to 2000, he took various positions in biotech companies in the San Francisco Bay Area, including Aviron, Clontech, and Rigel. In 2001, he founded Shanghai Genomics which was later merged with GNI Ltd. of Tokyo. GNI went public on the Tokyo Stock Exchange (TSE MOTHERS 2160) in 2007. He is currently Chairman, President and CEO of both Shanghai Genomics and GNI. From 2001, Dr. Luo has led three Chinese National 863 Hi-Tech Development Projects on drug target discovery and validation. He is also an adjunct faculty member and Director of Functional Genomics of the National Genome Center at Shanghai. In his career, he had co-authored more than 35 research publications in leading international journals of life sciences and wrote several review articles covering the changing trends of the Asian pharmaceutical industry. His venture experience in Shanghai was reported in the front page of the Wall Street Journal, Financial Times, Shanghai TV channels and other international media. In 2007, he was awarded the Magnolia Silver Medal by Shanghai Municipal Government for his contribution to the economic development and modernization of Shanghai.Appearing: Conference Day One: Wednesday, 17 March 2010 16.00 Advance early leads in pipeline to pre-IND stage using a combination of modern functional genomics, in-silico screening, and animal modeling platforms Dr Ying Luo, Chairman and CEO,
Shanghai Genomics, Inc/ GNI Ltd., China |
|
|
|
|
|
Session sponsor:
Exhibitors:
|
asia research institution poster presentation
* For first 20 confirmed poster presentations
|
|
|
|
|
|
|
|
|
